survodutide mastery course
Unit 10 of 12
The Incretin Landscape
survodutide vs semaglutide, tirzepatide, and retatrutide
The Metabolic Drug Landscape
Survodutide enters a competitive field that already includes semaglutide (GLP-1 mono-agonist), tirzepatide (GLP-1/GIP dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist). This unit compares receptor profiles, weight loss efficacy, liver effects, and market positioning across the incretin class to show where survodutide differentiates.
Interactive Compound Comparison
Compare receptor activity, clinical outcomes, and differentiation across the incretin drug class.
compound comparison matrix
key numbers
comparative efficacy across the incretin drug class.
15.2%
semaglutide weight loss (STEP 1, 68 weeks)
20.9%
tirzepatide weight loss (SURMOUNT-1, 72 weeks)
14.9%
survodutide weight loss (Phase 2, 46 weeks)
83%
survodutide MASH resolution (best-in-class Phase 2)
Cross-trial comparisons are inherently unreliable. Different patient populations, trial durations, dose ranges, and escalation schedules make head-to-head claims misleading. Survodutide's Phase 2 data (46 weeks, max 4.8 mg) cannot be directly compared to Phase 3 data from semaglutide or tirzepatide. The Phase 3 SYNCHRONIZE trials will provide a more valid comparison point.
key terms
competitive landscape vocabulary for this unit. tap to expand.
M
A drug that activates a single receptor type. Semaglutide is a GLP-1R mono-agonist. While effective for weight loss and glycemic control, it lacks the hepatic metabolic benefits that come from GCGR or GIPR engagement.
D
A drug that activates two receptor types. Survodutide (GLP-1/GCGR) and tirzepatide (GLP-1/GIP) are both dual agonists, but target different second receptors. The GCGR arm gives survodutide its liver-specific metabolic effects; the GIPR arm may reduce tirzepatide's GI side effects.
T
A drug that activates three receptor types. Retatrutide (GLP-1/GIP/GCGR) is the only triple agonist in advanced development. In Phase 2 it showed 24.2% weight loss and ~90% MASH resolution -- the highest reported for any single agent.
B
A compound with the strongest efficacy in a specific indication relative to competitors. Survodutide's positioning is best-in-class for MASH (83% resolution at highest Phase 2 dose) rather than overall weight loss, where retatrutide leads.
C
Cardiovascular outcomes trial. Required by the FDA for cardiometabolic drugs. Semaglutide completed its CVOT (SELECT) showing cardiovascular benefit. Tirzepatide and survodutide CVOTs are ongoing. A positive CVOT significantly expands a drug's market potential.
competitive positioning
where each compound sits in the landscape and the strategic niche it occupies.
semaglutide (Novo Nordisk)
first mover advantage. 10+ years of GLP-1 class safety data. positive CVOT. most established, but faces patent cliffs and mono-agonist limitations in MASH.
tirzepatide (Eli Lilly)
strongest weight loss among approved drugs (20.9%). GIP co-agonism may improve GI tolerability. MASH data (44-62% resolution) weaker than survodutide's.
survodutide (Boehringer Ingelheim)
best-in-class MASH data (62-83% resolution). GCGR arm drives unique hepatic benefits. Breakthrough Therapy + PRIME designations. competitive weight loss pending Phase 3 confirmation.
retatrutide (Eli Lilly)
highest weight loss (24.2%) and MASH resolution (~90%) of any single agent. triple agonist is first-in-class. Phase 3 ongoing. if confirmed, could leapfrog all competitors.